Adding immunotherapy to standard of care shows benefit compared with placebo and is confirmed to be practice-changing for this patient population
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
New subpopulation analyses from three international phase III trials confirm efficacy of immune checkpoint inhibitors across geographical areas
Positive results in intermediate and advanced disease come after the failure of global trials investigating the combination of TACE with targeted agents
Final overall survival results are now awaited to confirm the place of the combination treatment as a standard approach
Patients with resected stage II–III CRC may benefit from earlier detection of recurrence, enabling more to receive surgery with curative intent, but further work is needed to determine the most reliable and cost-effective methods of follow-up
Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles
Although further evidence is needed, targeting mutant KRAS with novel agents and combinations may offer new options for patients with advanced colorectal cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.